DOI: 10.3724/SP.J.1008.2015.01329

Academic Journal of Second Military Medical University (第二军医大学学报) 2015/36:12 PP.1329-1332

Population pharmacokinetics in individualized drug dosage regimes of valproate

Valproate is commonly used as a first-line broad-spectrum anti-epileptic drug. Valproate has a narrow therapeutic window, its metabolism is affected by many factors, and it has great individual differences, which makes individualized drug dosage regime needed for valproate. Population pharmacokinetics is a population analytical method developed in recent years. This paper reviewed the in vivo metabolic process and the population pharmacokinetics of valproate in recent years, and analyzed the factors that may affect the metabolism of valproate, including demographic factors, genetic factors and concomitant medications, hoping to provide reference for clinical individualized drug dosage regime.

Key words:valproate;population pharmacokinetics;individual treatment

ReleaseDate:2016-05-27 09:20:01

[1] 齐明山, 张 庆. CYP基因多态性与抗癫疒 间 药物代谢相关性的研究进展[J]. 中风与神经疾病杂志, 2012, 29:572-573.

[2] Zighetti M L, Fontana G, Lussana F, Chiesa V, Vignoli A, Canevini M P, et al. Effects of chronic administration of valproic acid to epileptic patients on coagulation tests and primary hemostasis[J]. Epilepsia, 2015, 56:e49-e52.

[3] 袁孔现, 毛名扬, 詹三华. HPLC测定血清中丙戊酸浓度质控方法的研究[J]. 河北医药, 2015, 37:613-615.

[4] 卢 建. 丙戊酸钠在儿科患者中的应用[J]. 实用儿科临床杂志, 1995, 10:173-174.

[5] Tan L, Yu J T, Sun Y P, Ou J R, Song J H, Yu Y. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients[J]. Clin Neurol Neurosurg, 2010, 112:320-323.

[6] Amini-Shirazi N, Ghahremani M H, Ahmadkhaniha R, Mandegary A, Dadgar A, Abdollahi M, et al. Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients[J]. Toxicol Mech Methods, 2010, 20:452-457.

[7] Kiang T K, Ho P C, Anari M R, Tong V, Abbott F S, Chang T K. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype[J]. Toxicol Sci, 2006, 94:261-271.

[8] Ghodke-Puranik Y, Thorn C F, Lamba J K, Leeder J S, Song W, Birnbaum A K, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics [J]. Pharmacogenet Genom, 2013, 23:236-241.

[9] Sagar K S, Duggirala N, Patel C Y, Acharya L D, Mallayasamy S. Design of drug dosage regimen for valproate: exploring modeling and simulation based approach[J]. Int J Pharmacol Clin Sci, 2014, 3:22-27.

[10] Aarons L. Population pharmacokinetics: theory and practice [J]. Br J Clin Pharmacol, 1991, 32: 669-670.

[11] Jiang D C, Wang L, Wang Y Q, Li L, Lu W, Bai X R. Population pharmacokinetics of valproate in Chinese children with epilepsy [J]. Acta Pharmacol Sin, 2007, 28:1677-1684.

[12] Serrano B B, García Sánchez M J, Otero M J, Buelga D S, Serrano J, Domínguez-Gil A. Valproate population pharmacokinetics in children [J]. J Clin Pharm Ther, 1999, 24:73-80.

[13] Fattore C, Messina S, Battino D, Croci D, Mamoli D, Perucca E. The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: a case-matched evalyation based on therapeutic drug monitoring data [J]. Epilepsy Res, 2006, 70: 153-160.

[14] Correa T, Rodriguez I, Romano S. Population pharmacokinetics of valproate in Mexican children with epilepsy [J]. Biopharm Drug Dispos, 2008, 29: 511-520.

[15] Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T. Poulation-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics [J]. J Clin Pharmacol, 1997, 37: 1160-1167.

[16] Lin W W, Jiao Z, Wang C L, Wang H Y, Ma C L, Huang P F, et al. Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen [J]. Ther Drug Monit, 2015, 37:76-83.

[17] Ho P C, Abbott F S, Zanger U M, Chang T K H. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes[J]. Pharmacogenomics J, 2003, 3:335-342.

[18] Jiang D C, Bai X R, Zhang Q X, Lu W, Wang Y, Li L, et al. Effects of CYP2C19 and CYP2C9 genotypes on the pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling[J]. Eur J Clin Pharmacol, 2009, 65: 1187-1193.

[19] 孙妍萍, 谭 兰, 王 雁, 宋敬卉. 尿苷二磷酸葡萄糖醛酸转移酶1A6基因多态性对丙戊酸钠代谢的影响[J]. 中华医学杂志, 2007, 87:2033-2035.

[20] Inouse K, Suzuki E, Yazawa R, Yamamoto Y, Takahashi T, Takahashi Y, et al. Influence of uridine diphosphate glucuronosyltransferase 2B7-161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients[J]. Ther Drug Monit, 2014, 36:406-409.

[21] Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse L M, Moltke L L V, Greenblatt D J. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: Ⅱ. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S) [J].J Pharmacol Exp Ther, 2005, 313:1340-1346.

[22] Chung J Y, Cho J Y, Yu K S, Kim J R, Lim K S, Sohn D R, et al. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects[J]. Clin Pharmacol Ther, 2008, 83:595-600.

[23] Ethell B T, Anderson G D, Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases[J]. Biochem Pharmacol, 2003, 65:1441-1449.

[24] 肖 湘. 群体药代动力学在儿科抗癫疒 间 药合理使用中的应用[J]. 淮海医药, 2014, 32:413-414.